Member Exclusive

UniQure in gene therapy deal with BMS

UniQure NV has secured a gene therapy agreement with Bristol-Myers Squibb Company in cardiovascular disease, its first major commercial deal since winning regulatory approval in 2012 for Glybera, a gene therapy for lipoprotein lipase deficiency.

Go to the profile of Victoria English
Apr 06, 2015
0
0

Please sign in or register for FREE

Register to RegMedNet – the regenerative medicine network

RegMedNet is a free content and networking hub promoting global connection, knowledge-sharing and collaboration between all members of the regenerative medicine field.

Register

No comments yet.